• Profile
Close

Enzalutamide with standard first-line therapy in metastatic prostate cancer

New England Journal of Medicine Jun 07, 2019

Davis ID, et al. - Through an open-label, randomized, phase 3 trial, researchers intended to assess the improvement in survival in men with metastatic, hormone-sensitive prostate cancer when enzalutamide is added to testosterone suppression, with or without early docetaxel. Testosterone suppression and open-label enzalutamide or a standard non-steroidal anti-androgen therapy was given to 1,125 patients. Treatment discontinuation was more commonly noted in the enzalutamide group due to toxic effects, like fatigue and seizures. Yet, significantly longer progression-free and overall survival vs standard care in men with metastatic, hormone-sensitive prostate cancer receiving testosterone suppression was noted.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay